R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms

Liang Wang¹, Lin-Rong Li²
¹Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China;
²Department of Breast Surgery, Peking Union Medical College Hospital, Beijing 100730, China.

Abstract
Although the first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone regimen (R-CHOP) substantially improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL), 40% of the patients suffered from relapsed/refractory disease and had poor survival outcomes. The detailed mechanism underlying R-CHOP resistance has not been well defined. For this review, we conducted a thorough search for literature and clinical trials involving DLBCL resistance. We discussed DLBCL biology, epigenetics, and aberrant signaling of the B-cell receptor (BCR), phosphatidylinositol 3-kinase (PI3K)/Akt, nuclear factor kappa light chain enhancer of activated B-cells (NF-κB), and the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathways as defining mechanisms of DLBCL heterogeneity and R-CHOP resistance. The cell of origin, double- or triple-hit lymphoma and double-protein-expression, clonal evolution, tumor microenvironment, and multi-drug resistance help to contextualize DLBCL resistance in an (epi)genetically and biologically comparative manner. With better understanding of the biological and molecular landscape of DLBCL, a more detailed classification system and tailored treatments will ideally become available to further improve the prognosis of DLBCL patients.

Keywords: Diffuse large B-cell lymphoma; Tumor microenvironment; Multi-drug resistance; Genetic heterogeneity

Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), comprising approximately 25% of the total mature NHL cases in the United States and 45.8% in China.¹,² Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has been considered as a standard first-line therapy following improvements in the prognosis of patients with DLBCL, resulting in a 10-year overall survival (OS) of 43.5%.³ However, 20% of the patients treated with R-CHOP had refractory disease, and approximately 20% of the patients who initially benefited from R-CHOP reported relapsed cases.⁴ The 30% to 50% of patients with primary or secondary resistance to R-CHOP had significantly poorer survival outcomes and a median OS for about 6.3 months.⁵ The mechanisms of R-CHOP resistance have not been adequately elucidated. For this review, we conducted a thorough search for literature and clinical trials involving DLBCL resistance and recapitulated the mechanisms of R-CHOP resistance regarding tumor biology and molecular pathways. Moreover, we addressed practical agents targeting each pathway, thus paving the road for future hierarchical classification and tailored treatments.

Tumor biology of R-CHOP resistance
Cell of origin
Gene expression profiling (GEP) analysis has defined activated B-cell-like (ABC) and germinal center B-cell-like (GCB) as the two major subtypes of DLBCL (approximately 50% and 30%, respectively), according to cell of origin (COO). GEP studies have shown that genes defining the ABC subgroup, such as interferon regulatory factor 4 (IRF4), FLICE-like inhibitory protein (FLIP), and B-cell lymphoma 2 (BCL-2), are normally induced during B cell proliferation and activation as characteristics of plasma cells.⁶ In contrast, the GCB subgroup exhibits genes that are preferentially expressed in germinal center B-cells, such as cluster of differentiation 10 (CD10), LIM domain only 2 (LMO2), and BCL-6.⁷ Intriguingly, recurrent enhancer of zeste 2 (EZH2) mutation, phosphatase and tensin homolog (PTEN) deletion, BCL-2 translocation/mutation, and c-REL amplification, which are common in the GCB subtype, are seldom described in the ABC subtype.⁸ The
The tumor microenvironment is considered to be a defining feature in B-cell differentiation and DLBCL tumorigenesis, including immune cells, stromal cells, and extracellular components [Figure 1]. The response to R-CHOP was affected by the pretreatment of tumor microenvironment concerning fibrosis, angiogenesis, and immune cells.\[11\] The tumor microenvironment was differentially constructed at the gene and protein levels when comparing R-CHOP-sensitive DLBCL with resistant DLBCL.\[16\] CD37 deficiency, programmed cell death-ligand 1 (PD-L1), and CD47 upregulation on malignant B-cells revealed immune evasion were observed in resistant cases.\[17,19\] However, it was found that CD47 upregulation correlated with poorer prognosis in patients with non-GCB DLBCL compared to the GCB subtype, thereby indicating that a distinct microenvironment existed in different COOs.\[20\] A CD47 blockade by Hu5F9-G4 can synergize with rituximab to overcome R-CHOP resistance in DLBCL.\[19\] Janus kinase-signal transducer and activator of transcription 3 (JAK-STAT3) signaling propagates several levels of intimate interaction between tumor cells and the immunological microenvironment to regulate angiogenesis, inflammation, immunosuppression, and oncogenesis.\[21\]

The apoptosis-protective adhesion to stromal cells, termed cell adhesion-mediated drug resistance (CAM-DR), is another underlying mechanism of R-CHOP resistance in DLBCL.\[22\] CAM-DR was revealed to correlate with
rituximab resistance through ADAM metalloproteinase domain 12 (ADAM-12) upregulation and phosphatidylinositol 3-kinase (PI3K)-Akt signaling modulation. However, as per findings reported by Lenz et al., genetically identified non-malignant signatures of stromal-1 (fibrosis and myeloid infiltration) and stromal-2 (vessel formation) in pretreatment biopsies were found to be prognostically favorable and unfavorable for patients with DLBCL who received R-CHOP, respectively. This finding was in concordance with a report by Cardesa-Salzmann et al. which stated that increased microvessel densities independently signified an inferior OS for patients with de novo DLBCL treated with R-CHOP.

**Multi-drug resistance**

Multi-drug resistance (MDR) describes acquired cross-resistance to a wide variety of structurally and functionally unrelated agents. The membrane protein P-glycoprotein (Pgp) ATP binding cassette-1 serves as an ATP-dependent efflux pump for the active removal of its substrates through the lipid bilayer and for the reduction in intracellular cytotoxic concentration, thereby resulting in MDR. Pgp is encoded by MDR-1, one of the most investigated MDR genes located on chromosome 7q21.12, where significant polymorphisms exist. In addition to Pgp, other transporters in the ATP-binding cassette transporter family have been identified to confer drug resistance, such as multidrug-resistance-related protein-1 (MRP-1) and ATP-binding cassette subfamily G member 2 (ABCG2). Oxaliplatin, vincristine, and prednisone are substrates for Pgp and are known to induce MDR-1 expression. DLBCL patients with high expression of Pgp, MRP-1, or ABCG2 demonstrated a significantly poor outcomes.

**Targeting molecular mechanisms in R-CHOP resistance**

The findings reported by Schmitz et al. and Chapuy et al. suggested a different targeted therapies for genetically distinct DLBCL subsets. For example, the perturbation of proximal B-cell receptor (BCR) signaling is suggested for the C5 and MCD subtypes, BCL-2 inhibitors for C5, NF-κB signaling blockade for C1 and BN2, and inhibition of JAK-STAT3 signaling for C4. Herein, we summarized the most investigated gene and protein aberrations in DLBCL as well as the cross-linked signaling pathway intricacies at the intersection of DLBCL biology and the clinic. These abnormalities are further elucidated by the perturbation of epigenetics in this study. Existing resistance to R-CHOP necessitates the use of alternative resistance modes.
strategies and individualized therapies. In this context, rational drugs under investigation targeting R-CHOP resistance are further enumerated and discussed on a molecular basis [Figure 2].

Double- or triple-hit lymphoma and double-expressor lymphoma

Double-hit lymphoma (DHL) and triple-hit lymphoma (THL) were embraced as a new category of high-grade B-cell lymphoma by the 2016 World Health Organization classification of tumors with MYC/8q24 translocation accompanied by rearrangement of BCL-2/18q21, BCL-6/3q27, or both.[30] Approximately 80% to 90% of the DHLs or 19% to 34% of the DLBCLs are also double-expressor lymphomas (DELs) with dual overexpression of c-MYC and BCL-2 detected by immunohistochemistry.[31] Patients with DHL, THL, or DEL were generally considered to have a poor outcomes in the era of R-CHOP; however, the prognostic value of BCL-2, BCL-6, or MYC remains controversial.[32,33] MYC plays a dominant role in proliferation, cell growth, apoptosis, and oncogenic transcription[34] while BCL-2 maintains cellular viability via apoptosis inhibition.[35] The dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen was shown to be a better choice for DLBCL patients with MYC translocation, although no randomized controlled trials have confirmed this so far.[36] Landsburg et al.[37] reported that ibrutinib monotherapy was highly effective in relapsed/refractory (rr) DEL. Regarding the overexpression of BCL-2 in DHL or DEL, BCL-2 inhibitor ABT-199 was demonstrated to result in an overall response rate (ORR) of 38% in rrDLBCL in a phase I trial.[38] In a HOVON phase II trial,[39] R-CHOP plus lenalidomide appeared to provide benefits to patients with MYC translocation.
translocation with a 2-year OS and disease-free survival (DFS) of 73% and 75%, respectively. A previous study showed that the XPO1 inhibitor could decrease c-MYC expression, and combined use of the BCL-2 and XPO1 inhibitors was highly effective in eradicating DHL cells in vitro and prolonging host survival in vivo in a mouse DHL model.[56]

**BCR signaling pathway**

The BCR signaling pathway exhibits a functionally determinant role in B-cell activation, proliferation, and differentiation. The constitutive activation of PI3K and phosphatidylinositol-dependent kinase 1 (PDK-1) is essential for the survival of ABC-DLBCL cells with chronic active BCR signaling.[43,44] Signaling adapters caspase-associated recruitment domain 11 (CARD11), BIMP3, CARD-containing MAGUK protein 1 (CARMA1), BCL-10, and mucosa-associated lymphoid tissue lymphoma translocation-1 (MALT-1) comprise the CARMA1–BCL-10–MALT-1 (CBM) complex, but it is an integral whole, contributes to the upregulation of constitutive NF-kB activation in ABC-DLBCL.[43] Additionally, the MALT-1 subunit of the CBM complex features indirect NF-kB-promoting activity via proteolysis of the NF-kB inhibitors CYLD, RELB, A20, and BCL-10.[44] Indeed, chronic-active BCR signaling plays a pivotal in the survival of almost all ABC-DLBCLs and driven by frequent activating mutations of the immunoreceptor tyrosine-based activation motifs in CD79B and CD79A or of the coiled-coil domain in CARD11.[44] In contrast, GCB-DLBCLs are prone to survive with a BCR-negative immunophenotype.[45]

Previous studies have provided a framework for targeted inhibition of the BCR signaling pathway in BCR-DLBCL.[44,46–52] Apart from COO algorithms, genetic assessments to confirm the exact lesion of the molecular pathways are recommended. For example, BTK inhibition is lethal for the upstream CD79B negative immune cells but dispensable for the downstream CARD11-mutant DLBCL, which would be killed by downstream blockade of the NF-kB pathway.[53]

**PI3K-Akt signaling pathway**

PI3K-Akt signaling activation is enabled by sequential phosphorylation of PI3K, phosphatidylinositol-4,5-bisphosphate (PIP2), and Akt/protein kinase B.[54] Akt directly activates NF-kB signaling via phosphorylated IkBs at Thr23[55] and indirectly activates NF-kB signaling by stimulating the mitogen-activated protein kinase (MAPK) family.[56] PTEN serves as a major negative regulator of PI3K-Akt signaling by dephosphorylating PIP3, and PI3K/Akt dysregulation was indicated in 55% of the GCB-DLBCLs and 14% of the non-GCB DLBCLs with PTEN deficiency.[57]

The PI3K-Akt signaling pathway is involved in rituximab action, chronic activation of BCR signaling, and CAM-DR. High levels of phosphorylated Akt had an adverse prognostic impact on patients with DLBCL treated with R-CHOP.[158] Conceivably, components of the PI3K-Akt signaling pathway exhibit validated targets of DLBCL. Everolimus and temsirolimus are rapamycin analogs that target the raptor mammalian target of rapamycin. In a phase II trial of everolimus for rrDLBCL, an ORR of 30% was reported.[59] Furthermore, single-agent ibritinib or copanlisib for inhibition of BTK or PI3K triggered simultaneous activation of the other pathway, thereby highlighting the significance of combined therapy.[42]

**NF-kB signaling pathway**

NF-kB signaling is activated by canonical (activates p50/rel and p50/relA) and non-canonical (activates p52/relB) pathways with both anti-apoptotic and apoptotic functions.[60] As downstream effectors of chronic active BCR signaling, the sustained activity of NF-kB signaling exerts a prominent tumor survival feature in ABC-DLBCL but not in GCB-DLBCL.[61] Both p50 and p65 activation proved to be unique mechanisms of R-CHOP resistance in ABC-DLBCL.[62,63] ABC-DLBCLs facilitate the canonical NF-kB signaling pathway by aberration of MYD88, BCL-10, CARD11, CD79A, CD79B, cyclin D2, CCR7, IRF4, FLIP, NFKBIA, TRAF2, and TNFAIP3.[64,65] Cells with MYD88 mutations exhibit constitutive activation of canonical NF-kB signaling.[60] Therefore, the target components of NF-kB signaling are of therapeutic importance. Lenalidomide and its analog thalidomide, which have antiangiogenic and pleiotropic immunomodulatory functions, exert direct tumor toxicity by binding to cereblon to inhibit downstream NF-kB signaling.[65] The regimen of lenalidomide plus R-CHOP appeared to mitigate the inferior survival of non-GCB DLBCLs in two phase II trials of 112 patients with newly diagnosed DLBCL.[66]

**JAK-STAT3 signaling pathway**

JAKs belong to the cytosolic tyrosine kinase family. JAKs are phosphorylated and activated upon cytokine binding. Subsequently, STAT proteins are activated and transition to the nucleus to facilitate transcription of downstream genes (eg, IL-6, IL-10, cyclin D1, cyclin D2, MYC, BCL-xl, and BCL-2), thereby influencing cell viability, immunosuppression, angiogenesis, and oncogenesis.[66] The STAT3-BCL-2-IL-10 loop is involved in R-CHOP resistance.[67] STAT3 expression was detected in 37% of the DLBCLs and in 54% of the ABC-DLBCLs treated with R-CHOP, thereby indicating poor survival, especially for the ABC subtype.[69] Conceivably, activation of the JAK-STAT3 signaling pathway of ABC-DLBCL suggests promising therapeutic targets, including JAK, STAT3, and IL-10 receptors.[70] According to results from a phase Ib trial, STAT3 antisense oligonucleotide AZD9150 showed efficacy in patients with rrNHL.[71]

**Epigenetics**

Epigenetic modifications confer crucial information to the transcription phenotypes and biological behaviors of tumorigenesis and drug resistance. Mutations of epigenetic modifiers (EP300, KMT2D, and SETDB1) were observed at both diagnosis and relapse, suggesting their roles as driver mutations of tumorigenesis in DLBCL.[13] Methyl-
However, proper classiﬁcation of DLBCL patients treated with R-CHOP using genetic, epigenetic, and cytogenetic approaches is critical. The BCR, PI3K-Akt, NF-

The COO, clonal evolution, tumor microenvironment, MDR, and epigenetics are important for biological considerations. Novel target agents based on these mechanisms are currently being used in preclinical and clinical trials of DLBCL. Although there is only modest evidence to support their roles as ﬁrst-line alternatives for R-CHOP, they must not be underestimated in the management of resistant DLBCL. Ideally, with better understanding of the biological and molecular landscape of DLBCL, a more detailed classiﬁcation system and tailored treatments will be available in the near future.

Conflicts of interest
None.

References
1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes: 2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes. CA Cancer J Clin 2016; 66:443–459. doi: 10.3322/caac.21357.

2. Chinese Society of Hematology CMA. Chinese guidelines for diagnosis and treatment of diffuse large B cell lymphoma (in Chinese). Chin J Hematol 2013;34:816. doi: 10.3760/cma.j.issn.0253-2727.2013.09.019.

3. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaing S, et al. Long-term outcome of patients in the LNH-96.5 trial, the ﬁrst randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–2045. doi: 10.1182/blood-2010-03-276246.

4. Wu JQ, Song CP, Su LP, Zhang MZ, Li W, Hu Y, et al. Three-year follow-up on the safety and effectiveness of rituximab plus chemotherapy as ﬁrst-line treatment of diffuse large B-cell lymphoma and follicular lymphoma in real-world clinical settings in China: A prospective, multicenter, noninterventional study. Chin Med J 2018;131:1767–1775. doi: 10.4103/cmj.cmj_2017_043.

5. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Karuvi J, West J, et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood 2017;130:1800–1808. doi: 10.1182/blood-2017-03-769620.

6. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identiﬁed by gene expression proﬁling. Nature 2000;403:503–511. doi: 10.1038/3500501.

7. Siow HC, Wu JQ, Wu Y, Du H, et al. CD20 repression and rituximab resistance detected in the peripheral blood mononuclear cells of DLBCL patients. Chin J Hematol 2016;31:139–142. doi: 10.3760/cma.j.issn.0253-2727.2016.06.026.

8. Tewari M, Wu JQ, Wu Y, et al. Expression of programmed cell death ligand 1 is associated with poor clinical outcomes in patients with diffuse large B-cell lymphoma: A prospective, multicenter, noninterventional study. Chin Med J 2018;131:1750–1757. doi: 10.4103/cmj.cmj_2017_009.

9. Tewari M, Wu JQ, Wu Y, et al. CD38 expression patterns and correlation with rituximab non-responder at diagnosis in DLBCL: A prospective, multicenter, noninterventional study. Chin Med J 2019;132:1156–1161. doi: 10.4103/cmj.cmj_2018_035.
33. Islam S, Paek AL, Hammer M, Rangarajan S, Ruijtenbeek R, Cooke et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin (α4-1 / VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011; 155:53-64. doi: 10.1111/j.1365-2321.2011.13653.v1.

34. Xin H, Zhong F, Ouyang Y, Wang Q, Ding L, He S. Upregulation of ALK, PAK, and PAK-activated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in non-Hodgkin’s lymphoma. Hematology (Amsterdam, Netherlands) 2017;22:527-535. doi: 10.1080/10245332.2017.1312205.

35. Cardesa-Salzmann TM, Colomo L, Gutierrez G, Chan WC, et al. Prognostic significance of BCL-2 and BCL-6 expression in MYC-positive large B-cell lymphoma with R-CHOP plus lenalidomide: Results of a multicenter HOVON phase II trial. Haematologica 2019; doi: 10.3324/haematol.2019.238162.

36. Liu Y, Azzizan NG, Dou Y, Pham LV, Li Y. Simultaneous targeting of VXS1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J Hematol Oncol 2019;12:119. doi: 10.1186/s12958-019-0803-9.

37. Kloo B, Nagel D, Pfeifer M, Grau M, Duwel M, Vincendeau M, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92. doi: 10.1038/nature08638.

38. Songal J, Souayah M, Wengner AM, Zittmann-Kolle S, Stutt A, Hake I, et al. Simultaneous inhibition of PJKdelta and PJKalpha induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-kappaB and AKT. Cancer Cell 2017;31:64-74. doi: 10.1016/j.ccell.2016.12.003.

39. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romeser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88-92. doi: 10.1038/nature08638.

40. Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, et al. Hereditary polymorphisms and pharmacological impact in MDR1, the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003;43:285-307. doi: 10.1146/annurev.pharmtox.43.100901.140233.

41. Kerb R, Höffner S, Brinkmann U. ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRPI and MRP2. Pharmacogenomics 2001;2:51-64. doi: 10.1517/14622416.2.1.51.

42. Kim J, Singh RR, Cheo-Vega JJ, Drakos E, Davuluri Y, Khoobfar F, et al. Gene expression signature including cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in non-Hodgkin’s lymphoma. Mod Pathol 2009;22:1312-1320. doi: 10.1038/modpathol.2009.98.

43. Ohswa M, Ikura Y, Fuchikuma H, Shirai N, Sugama Y, Suekane T, et al. Prognostic significance of BCL-2 and BCL-6 expression in MYC-positive large B cell lymphoma. Mod Pathol 2005;18:431-437. doi: 10.1038/modpathol.2005.56.

44. Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, et al. Hereditary polymorphisms and pharmacological impact in MDR1, the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003;43:285-307. doi: 10.1146/annurev.pharmtox.43.100901.140233.

45. Kerb R, Höffner S, Brinkmann U. ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRPI and MRP2. Pharmacogenomics 2001;2:51-64. doi: 10.1517/14622416.2.1.51.

46. Kim J, Singh RR, Cheo-Vega JJ, Drakos E, Davuluri Y, Khoobfar F, et al. Gene expression signature including cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in non-Hodgkin’s lymphoma. Mod Pathol 2009;22:1312-1320. doi: 10.1038/modpathol.2009.98.

47. Ohswa M, Ikura Y, Fuchikuma H, Shirai N, Sugama Y, Suekane T, et al. Prognostic significance of BCL-2 and BCL-6 expression in MYC-positive large B cell lymphoma. Mod Pathol 2005;18:431-437. doi: 10.1038/modpathol.2005.56.

48. Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, et al. Hereditary polymorphisms and pharmacological impact in MDR1, the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003;43:285-307. doi: 10.1146/annurev.pharmtox.43.100901.140233.

49. Kerb R, Höffner S, Brinkmann U. ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRPI and MRP2. Pharmacogenomics 2001;2:51-64. doi: 10.1517/14622416.2.1.51.

50. Kim J, Singh RR, Cheo-Vega JJ, Drakos E, Davuluri Y, Khoobfar F, et al. Gene expression signature including cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in non-Hodgkin’s lymphoma. Mod Pathol 2009;22:1312-1320. doi: 10.1038/modpathol.2009.98.

51. Ohswa M, Ikura Y, Fuchikuma H, Shirai N, Sugama Y, Suekane T, et al. Prognostic significance of BCL-2 and BCL-6 expression in MYC-positive large B cell lymphoma. Mod Pathol 2005;18:431-437. doi: 10.1038/modpathol.2005.56.
67. Calò V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, et al. STAT3 proteins: From normal control of cellular events to tumorigenesis. J Cell Physiol 2003;197:157–168. doi: 10.1002/jcp.10364.

68. Park YH, Sohn SK, Kim JG, Lee M-H, Song HS, Kim MK, et al. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy. Clin Cancer Res 2009;15:2107–2115. doi: 10.1158/1078-0432.CCR-08-1588.

69. Hwang X, Meng B, Iqbal J, Ding BR, Perry AM, Cao W, et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2013;31:4520–4528. doi: 10.1200/JCO.2012.45.6004.

70. Béguelin W, Sawh S, Chambers N, Chan FC, Jiang Y, Choo JW, et al. IL-10 receptor is a novel therapeutic target in DLBCLs. Leukemia 2015;29:1684–1694. doi: 10.1038/leu.2015.57.

71. Reilly MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, et al. STAT3 siRNA oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial. J Immunother Cancer 2018;6:119. doi: 10.1186/s40425-018-0436-5.

72. Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 2010;116:81–89. doi: 10.1182/blood-2010-05-285320.

73. Rui L, Drennan AC, Ceribelli M, Zhu F, Wright GW, Huang DW, et al. Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2016;113:E7260–E7267. doi: 10.1073/pnas.1609701113.

74. Yu X, Li Z. New insights into MicroRNAs involves in drug resistance in diffuse large B-cell lymphoma. Am J Transl Res 2015;7:2536–2542. PMID: 26882525.

75. Nie K, Zhang T, Allawi H, Gomez M, Liu Y, Chadburn A, et al. PTEN loss de-represses a lymphoma oncogene by sequence-specific epigenetic modifiers induces apoptosis in DLBCL. Leukemia 2016;30:1242–1245. doi: 10.1038/leu.2015.57.

76. Luo H, Schmidt JA, Lee Y-S, Oltz EM, Payton JE. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL. Leukemia 2017;31:77–86. doi: 10.1038/leu.2016.100.

77. Gupta M, Han JH, Stensson M, Welick L, Wirtz TE. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: Implications for therapy. Leukemia 2012;26:1336–1346. doi: 10.1038/leu.2011.340.

78. Luo H, Schmidt JA, Lee Y-S, Oltz EM, Payton JE. Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL. Leukemia 2017;31:77–86. doi: 10.1038/leu.2016.100.

79. Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 2013;3:1002–1019. doi: 10.1158/2159-8290.CD-13-0117.

80. Morschhauser F, Salles G, McKay P, Tilly H, Schmitt A, Gerecitano J, et al. Tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. Hematol Oncol 2017;35:24–34. doi: 10.1016/j.hol.2016.08.013.

81. How to cite this article: Wang L, Li LR. R-CHOP resistance in diffuse large B-cell lymphoma: biological and molecular mechanisms. Chin Med J 2021;134:253–260. doi: 10.1097/CM9.0000000000001294.